CSPC Pharmaceutical Group Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 2/6

CSPC Pharmaceutical Group verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 8%, während die Gewinne der Branche Pharmaceuticals jährlich um gewachsen und zwar um 5.7%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 8%. Die Eigenkapitalrendite von CSPC Pharmaceutical Group beträgt 14.3% und die Nettomargen betragen 17%.

Wichtige Informationen

8.0%

Wachstumsrate der Gewinne

8.2%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie	5.6%
Wachstumsrate der Einnahmen	8.0%
Eigenkapitalrendite	14.3%
Netto-Marge	17.0%
Letzte Ertragsaktualisierung	30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount?

Nov 15

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Oct 16

Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%

Sep 30

CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

Aug 08

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Jun 17

CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

May 29

CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

May 21

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

Apr 29

There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

Apr 22

CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

Apr 01

CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jan 22

Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

Jan 04

Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Oct 22

Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

Sep 21

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Jul 09

Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

Jun 20

CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

Jun 01

CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

Apr 04

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

Mar 12

Aufschlüsselung der Einnahmen und Ausgaben

Wie CSPC Pharmaceutical Group Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

SEHK:1093 Einnahmen, Ausgaben und Erträge (CNY Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Sep 24	30,271	5,157	9,948	5,032
30 Jun 24	31,654	5,927	10,303	5,069
31 Mar 24	32,380	6,057	10,872	4,992
31 Dec 23	31,450	5,873	10,330	4,830
30 Sep 23	31,306	6,118	10,410	4,744
30 Jun 23	31,407	6,092	10,973	4,406
31 Mar 23	31,116	6,116	11,177	4,093
31 Dec 22	30,937	6,091	11,510	3,987
30 Sep 22	30,721	5,738	11,915	3,845
30 Jun 22	29,655	5,509	11,611	3,704
31 Mar 22	29,007	5,538	11,700	3,643
31 Dec 21	27,867	5,605	11,453	3,433
30 Sep 21	26,369	5,977	10,747	3,132
30 Jun 21	26,175	5,908	10,703	3,050
31 Mar 21	25,551	5,472	10,332	3,013
31 Dec 20	24,942	5,160	10,323	2,890
30 Sep 20	24,558	4,421	10,522	2,765
30 Jun 20	23,515	4,150	10,287	2,511
31 Mar 20	22,735	3,922	10,050	2,108
31 Dec 19	22,103	3,714	9,461	2,000
30 Sep 19	21,335	3,625	8,887	1,928
30 Jun 19	20,135	3,454	8,202	1,725
31 Mar 19	18,835	3,294	7,426	1,543
31 Dec 18	17,717	3,081	6,841	1,342
30 Sep 18	16,877	2,905	6,337	1,346
30 Jun 18	15,729	2,734	5,664	973
31 Mar 18	13,959	2,443	4,839	912
31 Dec 17	12,877	2,307	4,178	679
30 Sep 17	12,203	2,195	3,747	277
30 Jun 17	11,659	2,068	3,410	282
31 Mar 17	11,383	1,979	3,203	0
31 Dec 16	11,075	1,881	2,992	0
30 Sep 16	10,439	1,711	2,725	0
30 Jun 16	10,118	1,607	2,576	0
31 Mar 16	9,656	1,473	2,419	0
31 Dec 15	9,545	1,395	2,347	0
30 Sep 15	9,284	1,305	2,202	0
30 Jun 15	9,072	1,192	2,045	0
31 Mar 15	8,919	1,126	1,938	0
31 Dec 14	8,762	1,015	1,871	0
30 Sep 14	8,423	896	1,748	0
30 Jun 14	8,197	849	1,686	0
31 Mar 14	8,001	814	1,627	0
31 Dec 13	7,768	760	1,500	0

Qualität der Erträge: 1093 hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: 1093Die aktuellen Gewinnspannen (17%) sind niedriger als im letzten Jahr (19.5%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: 1093In den letzten 5 Jahren sind die Gewinne von 8% jährlich gestiegen.

Beschleunigtes Wachstum: 1093Das Unternehmen hat im vergangenen Jahr ein negatives Gewinnwachstum verzeichnet, so dass es nicht mit seinem 5-Jahres-Durchschnitt verglichen werden kann.

Erträge im Vergleich zur Industrie: 1093 hatte im vergangenen Jahr ein negatives Gewinnwachstum (-15.7%), was einen Vergleich mit dem Branchendurchschnitt Pharmaceuticals (9.4%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: 1093Die Eigenkapitalrendite des Unternehmens (14.3%) wird als niedrig angesehen.

CSPC Pharmaceutical Group Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Executive Chairman recently bought HK$2.0m worth of stock

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount?

CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024

Investor sentiment deteriorates as stock falls 15%

Upcoming dividend of HK$0.16 per share

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA

Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%

Investor sentiment improves as stock rises 16%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares.

Executive Chairman recently bought HK$4.6m worth of stock

CSPC Pharmaceutical Group Limited Announces Aprepitant Injection Obtains Drug Registration Approval

Investor sentiment deteriorates as stock falls 17%

Executive Chairman recently bought HK$6.7m worth of stock

Price target decreased by 9.8% to HK$8.59

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024

CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces Enlonstobart Injection Obtains Conditional Marketing Approval

CSPC Pharmaceutical Group Limited Obtains Approval from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of HK$0.14 per share

CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug (JMT202) Obtains Approval from National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited to Report Q1, 2024 Results on May 27, 2024

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S

There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

Executive Chairman exercised options to buy HK$52m worth of stock.

CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval

CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate SYS6023 Obtains Clinical Trial Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024

CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration

Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA

CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets

CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023

CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE

CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval

Investor sentiment improves as stock rises 19%

CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors

Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA

Upcoming dividend of HK$0.14 per share at 4.7% yield

CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023